Module

Update on Targeted Therapies in Advanced NSCLC

Source: Targeted Therapies in the Treatment of Non-Small-Cell Lung Cancer

Update on Targeted Therapies in Advanced NSCLC

Faculty:
Roy S. Herbst, MD, PhD

CME CREDIT INFORMATION

Release Date: 01/12/07

Expiration Date: 01/11/08

Physicians: maximum of 0.5 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss the results of recent clinical studies of antiangiogenic agents combined with platinum-based chemotherapies in patients with advanced non-small-cell lung cancer
Describe the safety and efficacy of combining vascular endothelial growth factor and epidermal growth factor receptor inhibitors in the treatment of advanced non-small-cell lung cancer
Recall how EGFR inhibitors and other multi-targeted kinase inhibitors in development for NSCLC may impact clinical practice

Topics covered include:

Introduction
First-Line Treatment: Carboplatin/Paclitaxel Plus Bevacizumab
Selecting Appropriate Patients for Treatment With Bevacizumab
Erlotinib and Other EGFR-Specific Therapies in Advanced NSCLC
Multitargeted Kinase Inhibitors
Summary: Implications for Clinical Practice

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.